165
Participants
Start Date
February 2, 2021
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
Datopotamab deruxtecan
Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
Durvalumab
Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
Carboplatin
Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
AZD2936
Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
MEDI5752
Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
AZD7789
Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
Research Site, Taipei
Research Site, Taipei
Research Site, Hsinchu
Research Site, Tainan City
Research Site, Hasselt
Research Site, Ankara
Research Site, Barcelona
Research Site, Roeselare
Research Site, Orbassano
Research Site, Taipei
Research Site, A Coruña
Research Site, Philadelphia
Research Site, Fairfax
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Aviano
Research Site, Istanbul
Research Site, Izmir
Research Site, Taichung
Research Site, Seville
Research Site, Cleveland
Research Site, Meldola
Research Site, St Louis
Research Site, Dallas
Research Site, Houston
Research Site, San Antonio
Research Site, La Jolla
Research Site, Santa Ana
Research Site, Hackensack
Research Site, Roma
Research Site, Kōtoku
Research Site, Sunto-gun
Research Site, Yokohama
Research Site, Gdansk
Research Site, Lodz
Research Site, Lublin
Research Site, Warsaw
Research Site, Badalona
Research Site, Taoyuan District
Research Site, Adana
Research Site, Ankara
Lead Sponsor
Collaborators (1)
Daiichi Sankyo
INDUSTRY
AstraZeneca
INDUSTRY